Brief: Mannkind Says FDA Releases Company From Postmarketing Requirement For Afrezza On May 27 - SEC Filing
28/05/2026 13:55
BRIEF-Mannkind Says FDA Releases Company From Postmarketing Requirement For Afrezza On May 27 - SEC Filing May 28 (Reuters) - MannKind Corp MNKD.O:
FDA RELEASES MANNKIND FROM POSTMARKETING REQUIREMENT FOR AFREZZA ON MAY 27, 2026 - SEC FILING
Source text: [ID:n0001193125-26-243074]
Further company coverage: MNKD.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children